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Objectives
Decisions regarding choice and dose of anti-epileptic
drug (AED) are driven by considering the potential ben-
efits of reducing seizure frequency against the potential
harms of alternative AEDs. Such decisions should be
made using the best available evidence, which often
requires a quantitative synthesis of data from multiple
randomised controlled trials (RCT). However, the sys-
tematic review and meta-analysis of harms data is hin-
dered by problems such as inadequate reporting,
heterogeneity of harms definitions, and selective report-
ing bias. Here we will evaluate the quality of reporting
of harms data in epilepsy trials, and assess the potential
added value of incorporating harms data beyond the
clinical indication of epilepsy.
Methods
To evaluate the quality of reporting of harms data in
RCTs of AEDs in patients with epilepsy we have under-
taken a systematic review [1]. We searched MEDLINE,
the Cochrane Library and the Epilepsy Group register
for published trials comparing AEDs in patients with
epilepsy. Each trial was assessed according to a 23 item
checklist developed from the CONSORT statement for
the reporting of harms in clinical trials [2]. In a separate
analysis, Bayesian panoramic meta-analysis models [3]
were used to pool estimates of harm across studies and
across indications of epilepsy, neuropathy and headache,
allowing for variation between both study and
indication.
Results
For the reporting quality review we identified 152 RCTs
that met the eligibility criteria. None of the trials satis-
fied all criteria. The mean number of criteria per trial
was 11.3 (standard deviation 4.3, range 0 to 21). No
improvement could be detected following publication of
the CONSORT statement for harms (difference in
means: 0.6 with 95% CI (-0.9 to 1.8) p=0.53). Items that
were not frequently reported were; definition of adverse
events (36.2% of trials), use of a validated dictionary
(21.7% of trials), use of a validated instrument (15.8% of
trials), reporting of both number of patients and number
of adverse events (19.1% of trials) and methods for
handling of recurrent events (7.2% of trials). In the sum-
mary of harms data, borrowing strength from other
indications resulted in a more precise effect estimate,
and indicate that there is evidence for some adverse
events across the range of indications.
Conclusion
Reporting of harms in RCTs of AEDs is poor and has
not improved since the publication of the CONSORT
guidelines on the reporting of harms. To allow reliable
meta-analyses of harms data, improvements to reporting
quality are essential. Preliminary results suggest that
harms data from AEDs prescribed for headache and
neuropathy may be useful to inform the harms profile
of AEDs prescribed for epilepsy.
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